Review of pharmacotherapy for smoking cessation in patients with schizophrenia

Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to...

Full description

Saved in:

Bibliographic Details
Published in:	The mental health clinician Vol. 8; no. 2; pp. 78 - 85
Main Authors:	Shawen, Avery E, Drayton, Shannon J
Format:	Journal Article
Language:	English
Published:	United States College of Psychiatric & Neurologic Pharmacists 01-03-2018
Subjects:	Review of Pharmacotherapy varenicline schizophrenia nicotine replacement therapy smoking cessation bupropion
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2168-9709 2168-9709
DOI:	10.9740/mhc.2018.03.078